Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL7617251 | 1.00 | CHRM1 (0.78) | CHRM1CHRM4 | |
| Oxalic Acid SCHEMBL7614594 | 0.99 | CHRM1 (0.77) | CHRM1CHRM4 | |
| Oxalic Acid SCHEMBL7610942 | 0.98 | CHRM1 (0.77) | CHRM1CHRM4 | |
| SCHEMBL6914137 | 0.94 | CHRM1 (0.88) | CHRM1CHRM4 | |
| SCHEMBL7609424 | 0.94 | CHRM1 (0.88) | CHRM1CHRM4 | |
| SCHEMBL6940009 | 0.93 | CHRM1 (0.88) | CHRM1CHRM4 | |
| SCHEMBL6915595 | 0.92 | CHRM1 (0.88) | CHRM1CHRM4 | |
| Oxalic Acid SCHEMBL7619270 | 0.91 | CHRM1 (0.79) | CHRM1CHRM4 | |
| Tazomeline SCHEMBL7615741 | 0.91 | CHRM1 (0.79) | CHRM1CHRM4 | |
| Oxalic Acid SCHEMBL7619712 | 0.91 | CHRM1 (0.79) | CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | disclosed |
| US-5773452-A | ALZHEIMER'S DISEASE; COGNITION ACTIVATORS | NOVO NORDISK ALS (DK) | 1998-06-30 | — | — | US | disclosed |
| US-5753683-A | SCHIZOPHRENIA | NOVO NORDISK A/S (DK) | 1998-05-19 | — | — | US | disclosed |
| US-5750541-A | 3-(1,2,5-THIA OR OXADIAZOL-3-YL)-1,2,5,6-PYRIDINE DERIVATIVES; SCHIZOPHRENIFORM DISEASES; SIDE EFFECT REDUCTION | NOVO NORDISK A/S (DK) | 1998-05-12 | — | — | US | disclosed |
| US-5744489-A | ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS | GREENWOOD BEVERLEY (US) | 1998-04-28 | — | — | US | disclosed |
| US-5565475-A | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives | MUHLHAUSER MARK A (US) | 1996-10-15 | — | — | US | disclosed |
| US-5545638-A | USING A 3-(TETRAHYDROPYRID-3-YL-) SUBSTITUTED (OXA- OR THIA-)DIAZOLE COMPOUND | NOVO NORDISK A/S (DK) | 1996-08-13 | — | — | US | disclosed |